Pancreatic cancer is one of the deadliest cancers and is known for being chemoresistant. Despite utilizing new combinations of drugs and radiation, outcomes remain dismal while average incidence and death rates remain unchanged. Pancreatic cancer is recalcitrant to treatment because of the difficulties in transporting drugs to tumor sites due to unique physiological barriers. Therefore, our approach is to deliver drugs site selectively and to track delivery in real time. Furthermore, we will use focused ultrasound (FUS) to trigger drug release, which will increase ablation capabilities of FUS alone. This will therefore allow tissue heating to be combined with high local drug concentrations, which will kill tumor cells in a preclinical model
No reports found.